Literature DB >> 29420116

Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia.

Vesa Lindström1, Janne Aittoniemi2, Urpu Salmenniemi3, Helena Käyhty4, Heini Huhtala5, Maija Itälä-Remes6, Marjatta Sinisalo7.   

Abstract

Patients with chronic lymphocytic leukemia (CLL) are at a high risk for infections caused by Streptococcus pneumoniae. A pneumococcal conjugate vaccine (PCV) can induce a significant antibody response for some CLL patients. In this study we investigated antibody persistence after PCV7 in patients with CLL. The study material comprised 24 patients with CLL and 8 immunocompetent controls. The median antibody concentrations five years after PCV7 were lower for six pneumococcal serotypes in patients with CLL compared to controls, but the difference was not statistically significant. Depending on the serotype, the percentage of the CLL patients with antibody levels suggested to provide protection against invasive pneumococcal disease (IPD) varied from 29 to 71% five years after vaccination. This data suggests that PCV could result in antibody persistence at least five years in CLL patients.

Entities:  

Keywords:  antibody persistence; chronic lymphocytic leukemia; pneumococcal conjugate vaccine

Mesh：

Substances：

Year:  2018        PMID： 29420116      PMCID： PMC6037466          DOI： 10.1080/21645515.2018.1436424

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  15 in total

Review 1.  Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

Authors:  Luis Jódar; Jay Butler; George Carlone; Ron Dagan; David Goldblatt; Helena Käyhty; Keith Klugman; Brian Plikaytis; George Siber; Robert Kohberger; Ih Chang; Thomas Cherian
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

2.  Disease-specific complications of chronic lymphocytic leukemia.

Authors:  Claire Dearden
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2008

3.  Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial.

Authors:  C Cordonnier; M Labopin; C Robin; P Ribaud; L Cabanne; C Chadelat; S Cesaro; P Ljungman
Journal:  Bone Marrow Transplant       Date:  2015-04-13       Impact factor: 5.483

4.  Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia.

Authors:  M Sinisalo; J Aittoniemi; P Oivanen; H Käyhty; R M Olander; J Vilpo
Journal:  Br J Haematol       Date:  2001-07       Impact factor: 6.998

5.  Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.

Authors:  Robert W Frenck; Anne Fiquet; Alejandra Gurtman; Martin van Cleeff; Matthew Davis; John Rubino; William Smith; Vani Sundaraiyer; Mohinder Sidhu; Emilio A Emini; William C Gruber; Daniel A Scott; Beate Schmoele-Thoma
Journal:  Vaccine       Date:  2016-05-05       Impact factor: 3.641

6.  Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy.

Authors:  Mark J Abzug; Lin Ye Song; Myron J Levin; Sharon A Nachman; William Borkowsky; Stephen I Pelton
Journal:  Vaccine       Date:  2013-08-14       Impact factor: 3.641

7.  Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia.

Authors:  A Hartkamp; A H Mulder; G T Rijkers; H van Velzen-Blad; D H Biesma
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

Review 8.  Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis.

Authors:  Martha S Linet; Mary K Schubauer-Berigan; Dennis D Weisenburger; David B Richardson; Ola Landgren; Aaron Blair; Sharon Silver; R William Field; Glyn Caldwell; Maureen Hatch; Graça M Dores
Journal:  Br J Haematol       Date:  2007-12       Impact factor: 6.998

9.  Effects of ageing and gender on naturally acquired antibodies to pneumococcal capsular polysaccharides and virulence-associated proteins.

Authors:  Birgit Simell; Mika Lahdenkari; Antti Reunanen; Helena Käyhty; Merja Väkeväinen
Journal:  Clin Vaccine Immunol       Date:  2008-07-02

10.  The effect of ranitidine on antibody responses to polysaccharide vaccines in patients with B-cell chronic lymphocytic leukaemia.

Authors:  Ankie M T Van der Velden; Heleen Van Velzen-Blad; Anke M E Claessen; René Van der Griend; Ruud Oltmans; Ger T Rijkers; Douwe H Biesma
Journal:  Eur J Haematol       Date:  2007-05-28       Impact factor: 2.997
View more
  2 in total

1.  Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia.

Authors:  Vesa Lindström; Janne Aittoniemi; Urpu Salmenniemi; Helena Käyhty; Heini Huhtala; Marjatta Sinisalo
Journal:  Hum Vaccin Immunother       Date:  2019-07-09       Impact factor: 3.452

2.  Incidence and Predictors of Community-Acquired Pneumonia in Patients With Hematological Cancers Between 2016 and 2019.

Authors:  Maria Certan; Hannah M Garcia Garrido; Gino Wong; Jarom Heijmans; Martin P Grobusch; Abraham Goorhuis
Journal:  Clin Infect Dis       Date:  2022-09-29       Impact factor: 20.999
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.